Compounded Semaglutide vs Survodutide
A side-by-side research comparison of Compounded Semaglutide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Compounded Semaglutide | Survodutide |
|---|---|---|
| Full name | Compounded Semaglutide (503B Pharmacy) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Compounded medication | Phase 3 Clinical Trial |
| Mechanism | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 4113.58 Da | 4,500 Da (approximate) |
| Half-life | ~7 days | 5-7 days |
| Bioavailability | ~89% subcutaneous | High (SubQ) |
| Typical dose | 0.25-2.4 mg | 0.6-6.0 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.